Applied Molecular Transport

Biotechnology ResearchCalifornia, United States51-200 Employees

Applied Molecular Transport is a public biotechnology company based in South San Francisco, California, focused on developing oral biologic therapies for severe autoimmune, metabolic, and inflammatory diseases. It seeks to deliver these therapies by crossing the intestinal epithelium to access GI tissue, the hepatic portal system, and systemic circulation, aiming to achieve efficacy and tolerability not typically seen with conventional biologics. The company relies on proprietary technology platforms to create gastrointestinal-select biologics that modulate the immune system at its origin.

Its lead program, AMT-101, is an oral interleukin-10 fusion protein in Phase 1b for ulcerative colitis, designed to act directly within the GI immune environment where up to 75 percent of immune cells reside. The organization maintains a broad global IP portfolio and has pursued corporate development activities in recent years, including a 2023 merger with Cyclo Therapeutics.

Sign up for free to view info

Email Format Employee directory